{"id":"hydrocodone-acetaminophen-on-extended-release","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Dizziness"},{"rate":"20-30","effect":"Drowsiness"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Headache"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL1647","moleculeType":"Small molecule","molecularWeight":"327.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrocodone acts as a mu opioid receptor agonist, modulating pain perception and emotional response to pain in the brain and spinal cord. Acetaminophen works through inhibition of cyclooxygenase enzymes, reducing prostaglandin production and providing complementary analgesia. The extended-release formulation delivers both agents over an extended period to maintain sustained pain relief.","oneSentence":"Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:55.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain requiring opioid therapy"}]},"trialDetails":[{"nctId":"NCT00314340","phase":"PHASE4","title":"A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2005-11","conditions":"Chronic Pain","enrollment":12},{"nctId":"NCT00761150","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-09","conditions":"Chronic Low Back Pain","enrollment":308},{"nctId":"NCT00763321","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-09","conditions":"Chronic Low Back Pain","enrollment":287},{"nctId":"NCT00195728","phase":"PHASE3","title":"Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain","status":"COMPLETED","sponsor":"Abbott","startDate":"2005-06","conditions":"Moderate to Severe Chronic, Non-malignant Pain","enrollment":431}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-712"],"phase":"phase_3","status":"active","brandName":"Hydrocodone/Acetaminophen on Extended Release","genericName":"Hydrocodone/Acetaminophen on Extended Release","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects. Used for Moderate to severe pain requiring opioid therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}